يعرض 1 - 10 نتائج من 641 نتيجة بحث عن '"Banerjee, Susana"', وقت الاستعلام: 0.81s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    مؤتمر
  5. 5
    دورية أكاديمية

    المصدر: The Lancet. 399(10324)

    وصف الملف: application/pdf

  6. 6
    مؤتمر
  7. 7
    دورية أكاديمية

    المصدر: MEDIOLA Investigators , Drew , Y , Kim , J W , Penson , R T , O'Malley , D M , Parkinson , C , Roxburgh , P , Plummer , R , Im , S A , Imbimbo , M , Ferguson , M , Rosengarten , O , Steeghs , N , Kim , M H , Gal-Yam , E , Tsoref , D , Kim , J H , You , B , De Jonge , M , Lalisang , R , Gort , E , Bastian , S , Meyer , K , Feeney ....

    وصف الملف: application/pdf

  8. 8
    دورية أكاديمية
  9. 9
    دورية أكاديمية
  10. 10
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Meric-Bernstam F Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX. Makker V Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY. Department of Medicine, Weill Cornell Medical College, New York, NY. Oaknin A Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Oh DY Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea. Banerjee S Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom. Gonzalez-Martín A Medical Oncology Department and Programme in Solid TumoursCIMA, Cancer Center Clínica Universidad de Navarra, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Journal of Clinical Oncology;42(1); https://doi.org/10.1200/JCO.23.02005Test; Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024 Jan;42(1):47–58.; https://hdl.handle.net/11351/10905Test; 001130404400013